Neogen Q4 revenue down 0.1% to $225.3M; net loss $11.3M vs $612.2M loss a year ago
Neogen reported fiscal fourth-quarter 2026 revenue of $225.3 million, down 0.1% from a year earlier, with core revenue growth of 4.3%. The net loss narrowed sharply from $612.2 million a year earlier, which included a $597.9 million goodwill impairment, and the company gave fiscal 2027 revenue guidance of $880 million to $885 million and adjusted EBITDA of $180 million to $182 million.
Key points
- Q4 fiscal 2026 revenue $225.3 million vs $225.5 million a year earlier; full fiscal year revenue $870.4 million, down 2.7%
- Q4 net loss $11.3 million, or $(0.05) per diluted share, vs $(2.82) a year earlier; adjusted EPS $0.09 vs $0.05
- Q4 adjusted EBITDA $45.4 million, margin 20.2%, vs $40.6 million and 18.0% a year earlier
- FY27 guidance: revenue $880 million to $885 million and adjusted EBITDA about $180 million to $182 million, excluding the pending Genomics sale to Zoetis Inc. details to be updated later
The filing
Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.